Multiple Sclerosis Disease-Modifying Therapies: What They Cost

Multiple sclerosis (MS) is a chronic condition that often requires long-term medication to slow disease progression. The drugs used for this purpose — called disease-modifying therapies (DMTs) — are among the most expensive medications in the U.S. healthcare system. Understanding what drives those costs, and what can reduce them, helps patients and caregivers navigate coverage conversations more effectively.

What Are Disease-Modifying Therapies?

DMTs don't treat MS symptoms directly. Instead, they work by modifying how the immune system behaves to reduce the frequency and severity of relapses and, in many cases, slow the accumulation of disability over time.

There are now more than 20 FDA-approved DMTs for MS, spanning several different forms of the disease — primarily relapsing forms (including relapsing-remitting MS) and, more recently, progressive forms. They come in different formats:

• Oral medications (taken as pills or capsules)
• Injectable medications (self-administered at home)
• Infusion therapies (administered in a clinic or infusion center, sometimes once or twice a year)

The format matters for cost, convenience, and how insurance tends to classify and reimburse the drug.

Why Do MS DMTs Cost So Much? 💊

DMT list prices are notoriously high — often ranging from tens of thousands to well over $100,000 per year at list price (also called the "sticker price" before any discounts, rebates, or coverage apply). Several factors drive this:

• Research and development costs for biologics and specialty drugs are substantial
• Small patient populations mean manufacturers can't spread costs across mass-market volumes
• Patent protection limits competition for brand-name drugs
• Specialty drug classification places DMTs in high tiers on most insurance formularies

It's important to understand that list price is rarely what anyone actually pays. The real cost to a patient depends on a layered system of insurance, manufacturer programs, and pharmacy benefit structures.

How Insurance Affects What You Pay

For most patients, insurance is the primary factor shaping out-of-pocket costs. The key variables include:

Type of insurance coverage

• Private/employer insurance, Marketplace plans, Medicare, and Medicaid each handle specialty drugs differently
• Some plans cover DMTs under the pharmacy benefit (you pick it up at a pharmacy); others cover infusion therapies under the medical benefit (billed like a medical procedure). This distinction significantly affects cost-sharing.

Formulary tier placement

• Most insurers place DMTs in Tier 4 or Tier 5 (specialty tier), which typically carries the highest cost-sharing — often a percentage of the drug's cost rather than a flat copay
• Prior authorization is almost universal for DMTs; your neurologist documents why the specific therapy is medically necessary

Deductibles and out-of-pocket maximums

• A plan with a high deductible may require paying thousands of dollars before coverage kicks in
• Once an annual out-of-pocket maximum is met, most costs stop — but reaching it can take months

Medicare-specific considerations

• Under traditional Medicare Part D, DMTs in pill or injection form fall under the pharmacy benefit; infused DMTs often fall under Part B
• Historically, Medicare lacked an out-of-pocket cap for Part D drugs, though recent policy changes have begun to address this — checking current rules matters here

The Role of Manufacturer Assistance Programs 🤝

Pharmaceutical manufacturers that make DMTs typically offer patient assistance programs (PAPs) and copay assistance cards to reduce out-of-pocket costs for eligible patients.

• Copay cards can reduce or eliminate copays for commercially insured patients (those with private or employer insurance), sometimes to a nominal amount
• Patient assistance programs may provide the drug at low or no cost to uninsured or underinsured patients who meet income criteria
• These programs vary by manufacturer, drug, and a patient's insurance status — what's available for one DMT may not exist for another

Important caveat: Copay cards typically cannot be used by patients enrolled in federal programs like Medicare or Medicaid. Different rules apply for those populations.

Generic and Biosimilar Options

A meaningful shift in the DMT cost landscape has begun with the arrival of generics for some older oral DMTs and biosimilars for some injectable therapies.

• Generic versions of established DMTs can cost substantially less than their brand-name counterparts
• Biosimilars — which are highly similar versions of biologic drugs — are beginning to enter the MS market and may offer additional cost relief over time
• Whether a generic or biosimilar is appropriate for a given patient is a clinical decision, not just a financial one

The availability and formulary placement of these alternatives varies by insurer and plan year.

What Determines Your Actual Out-of-Pocket Cost

Practical Steps for Understanding Your Costs 📋

If you or someone you care for is starting or currently on a DMT, these are the areas worth investigating:

1. Review your plan's formulary — confirm the specific DMT's tier and cost-sharing structure before filling
2. Clarify medical vs. pharmacy benefit — especially for infused therapies, which can be billed very differently
3. Contact the manufacturer — ask directly about copay cards or patient assistance eligibility
4. Ask about specialty pharmacy options — some plans mandate a specific specialty pharmacy; others allow choice, and price and service can vary
5. Understand the timing of your deductible — costs can spike at the start of each plan year before the deductible is met
6. Work with your neurologist's office — many MS specialty practices have staff who help patients navigate coverage and assistance programs

The actual dollar amount any individual pays for a DMT can range from nearly nothing — with assistance programs and strong coverage — to several thousand dollars annually, or more. The spread is wide enough that two patients on the same drug can have radically different experiences based solely on their coverage and eligibility for support programs.

What This Means for Long-Term Planning

Because DMTs are typically taken indefinitely, cost management is not a one-time problem. Insurance plans change annually, formularies are updated, assistance programs have enrollment deadlines, and biosimilar availability will likely expand. Patients managing MS long-term benefit from revisiting their coverage situation each year during open enrollment and whenever their treatment changes.

The landscape is complex — but it's navigable with the right information and the right questions.